Latest filing published 07 Jan 2011 for Regenerx Biopharmaceuticals INC, €263k.
Insider track record
No signal scores available.
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -46.3%Entry US$27.00 · Close at T+365 US$14.50
- -10.0%Entry US$9,600.00 · Close at T+365 US$8,640.00
- -47.3%Entry US$99.00 · Close at T+365 US$52.14
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Claudio Cavazza: trading record in brief
This profile gathers the share dealings of Claudio Cavazza across 3 companies, led by Sciclone Pharmaceuticals Inc, Regenerx Biopharmaceuticals Inc and Soligenix, Inc. In total, 38 filings cover trades dated from 6 March 2006 to 5 January 2011.
The open-market record is one-sided, with 37 purchases worth €14.9M and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant. 2011 to date brings 2 purchases and no sales.
Half of the purchases are above €41k and half below. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 67% of cases, with a median move of +20.0%. These figures describe past trades and do not predict future prices.
The record was last updated on 7 January 2011 with an open-market purchase (€263k) in Regenerx Biopharmaceuticals Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Claudio Cavazza
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,296,296 shares@ US$0.27Common StockSEC:0001140361-11-001839:0Canonical exit: 5 Apr 2011 (T+90)
- 8,608,580 shares@ US$0.205Common StockSEC:0001140361-10-026305:0Canonical exit: 16 Sept 2010 (T+90)
- 3,952,569 shares@ US$0.253Common StockSEC:0001140361-09-021819:0Canonical exit: 23 Dec 2009 (T+90)
- 25,000,000 shares@ US$0.18Common StockSEC:0001140361-09-003868:0Canonical exit: 12 May 2009 (T+90)
- 2,500,000 shares@ US$1.00Common StockSEC:0001140361-08-005565:0Canonical exit: 29 May 2008 (T+90)
- 28,600 shares@ US$2.05Common StockSEC:0001140361-08-002494:0Canonical exit: 29 Apr 2008 (T+90)
- 7,035 shares@ US$2.01Common StockSEC:0001140361-08-001858:0Canonical exit: 21 Apr 2008 (T+90)
- 22,098 shares@ US$2.01Common StockSEC:0001140361-08-001858:1Canonical exit: 22 Apr 2008 (T+90)
- 28,001 shares@ US$2.00Common StockSEC:0001140361-08-001356:0Canonical exit: 10 Apr 2008 (T+90)
- 40,255 shares@ US$2.05Common StockSEC:0001140361-07-021240:0Canonical exit: 3 Feb 2008 (T+90)
- 25,000 shares@ US$2.05Common StockSEC:0001140361-07-020069:0Canonical exit: 15 Jan 2008 (T+90)
11 of 11 declarations